Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISCERN: Cemiplimab in Neoadjuvant Cutaneous Squamous Cell Carcinoma
NCT05878288Phase 2Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- May 2023
- Primary completion
- May 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Peter MacCallum Cancer Centre. Started May 2023; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05878288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878288.